Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404415 · ClinicalTrials.gov registry record
The Vanderbilt Atrial Fibrillation Ablation Registry
A clinical trial of Atrial Fibrillation, sponsored by Vanderbilt University.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT02404415: Recruiting study of Atrial Fibrillation, sponsored by Vanderbilt University.
NCT02404415 is a study of Atrial Fibrillation that is actively recruiting participants, run by Vanderbilt University. The registered enrollment target is 3,000 participants, roughly in line with the 2,982-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02404415, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by Vanderbilt University.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2011-10 |
| Est. Completion | 2028-10 |
What NCT02404415 shows while recruiting
NCT02404415 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,982-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT02404415 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02404415 about?
NCT02404415 is a clinical study titled "The Vanderbilt Atrial Fibrillation Ablation Registry". The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA...
What is the current status of trial NCT02404415?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2011-10. Estimated completion is 2028-10.
What conditions does trial NCT02404415 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
Who is sponsoring clinical trial NCT02404415?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02404415 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02404415's enrollment target sits among peer trials
3,000 21st of 202 higher than 180 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia